User login
Key clinical point: Long-term use of major classes of antihypertensive drugs was unlikely to be associated with an increased risk for colorectal cancer (CRC).
Major finding: Compared with never use, ≥11-year use of beta-blockers (adjusted hazard ratio [aHR] 1.38; 95% CI 0.90-2.11), calcium channel blockers (aHR 0.92; 95% CI 0.57-1.46), thiazide diuretics (aHR 0.84; 95% CI 0.47-1.51), angiotensin-converting enzyme inhibitors (aHR 0.57; 95% CI 0.23-1.39), or other antihypertensive drugs (aHR 1.12; 95% CI 0.59-2.12) was not associated with an increased risk for CRC.
Study details: This was a prospective cohort study of eligible participants from the Nurses’ Health Study and the Health Professionals Follow-up Study who were followed-up for 28 years.
Disclosures: This study was supported by the American Cancer Society Mentored Research Scholar Grant, US National Institutes of Health, World Cancer Research Fund, and others. Dr. Meyerhardt and Dr. Chan declared receiving institutional research funding from and consulting for various sources.
Source: Zhang Y et al. Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: A prospective cohort study. Br J Cancer. 2022 (Sep 22). Doi: 10.1038/s41416-022-01975-4
Key clinical point: Long-term use of major classes of antihypertensive drugs was unlikely to be associated with an increased risk for colorectal cancer (CRC).
Major finding: Compared with never use, ≥11-year use of beta-blockers (adjusted hazard ratio [aHR] 1.38; 95% CI 0.90-2.11), calcium channel blockers (aHR 0.92; 95% CI 0.57-1.46), thiazide diuretics (aHR 0.84; 95% CI 0.47-1.51), angiotensin-converting enzyme inhibitors (aHR 0.57; 95% CI 0.23-1.39), or other antihypertensive drugs (aHR 1.12; 95% CI 0.59-2.12) was not associated with an increased risk for CRC.
Study details: This was a prospective cohort study of eligible participants from the Nurses’ Health Study and the Health Professionals Follow-up Study who were followed-up for 28 years.
Disclosures: This study was supported by the American Cancer Society Mentored Research Scholar Grant, US National Institutes of Health, World Cancer Research Fund, and others. Dr. Meyerhardt and Dr. Chan declared receiving institutional research funding from and consulting for various sources.
Source: Zhang Y et al. Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: A prospective cohort study. Br J Cancer. 2022 (Sep 22). Doi: 10.1038/s41416-022-01975-4
Key clinical point: Long-term use of major classes of antihypertensive drugs was unlikely to be associated with an increased risk for colorectal cancer (CRC).
Major finding: Compared with never use, ≥11-year use of beta-blockers (adjusted hazard ratio [aHR] 1.38; 95% CI 0.90-2.11), calcium channel blockers (aHR 0.92; 95% CI 0.57-1.46), thiazide diuretics (aHR 0.84; 95% CI 0.47-1.51), angiotensin-converting enzyme inhibitors (aHR 0.57; 95% CI 0.23-1.39), or other antihypertensive drugs (aHR 1.12; 95% CI 0.59-2.12) was not associated with an increased risk for CRC.
Study details: This was a prospective cohort study of eligible participants from the Nurses’ Health Study and the Health Professionals Follow-up Study who were followed-up for 28 years.
Disclosures: This study was supported by the American Cancer Society Mentored Research Scholar Grant, US National Institutes of Health, World Cancer Research Fund, and others. Dr. Meyerhardt and Dr. Chan declared receiving institutional research funding from and consulting for various sources.
Source: Zhang Y et al. Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: A prospective cohort study. Br J Cancer. 2022 (Sep 22). Doi: 10.1038/s41416-022-01975-4